中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
23期
104-105
,共2页
黄斑视网膜厚度%视力%玻璃体腔注射治疗%雷珠单抗
黃斑視網膜厚度%視力%玻璃體腔註射治療%雷珠單抗
황반시망막후도%시력%파리체강주사치료%뢰주단항
Macular thickness%Vision%Intravitreal treatment%Ranibizumab
目的：探讨玻璃体腔注射雷珠单抗治疗脉络膜新生血管的临床效果。方法随机选取该院于2012年2月—2015年1月收治的脉络膜新生血管患者80例，根据随机抽签原则分为治疗组与对照组各40例，所有患者都给予玻璃体腔注射药物治疗，治疗组与对照组分别于角膜缘后4 mm左右垂直进针，缓慢推注雷珠单抗0.05 mL(1 mg/0.1 mL)和贝伐单抗0.05 mL(1mg/0.1 mL)。结果术后1个月进行调查，治疗组的视力有效率为97.5%，对照组为87.5%，治疗组的视力有效率明显高于对照组(P<0.05)。术后1个月两组的黄斑视网膜厚度与术前对比差异有统计学意义(P<0.05)，同时治疗组术后1个月的黄斑视网膜厚度明显少于对照组(P<0.05)。结论玻璃体腔注射雷珠单抗治疗脉络膜新生血管能有效降低黄斑视网膜厚度，从而提高术后视力。
目的：探討玻璃體腔註射雷珠單抗治療脈絡膜新生血管的臨床效果。方法隨機選取該院于2012年2月—2015年1月收治的脈絡膜新生血管患者80例，根據隨機抽籤原則分為治療組與對照組各40例，所有患者都給予玻璃體腔註射藥物治療，治療組與對照組分彆于角膜緣後4 mm左右垂直進針，緩慢推註雷珠單抗0.05 mL(1 mg/0.1 mL)和貝伐單抗0.05 mL(1mg/0.1 mL)。結果術後1箇月進行調查，治療組的視力有效率為97.5%，對照組為87.5%，治療組的視力有效率明顯高于對照組(P<0.05)。術後1箇月兩組的黃斑視網膜厚度與術前對比差異有統計學意義(P<0.05)，同時治療組術後1箇月的黃斑視網膜厚度明顯少于對照組(P<0.05)。結論玻璃體腔註射雷珠單抗治療脈絡膜新生血管能有效降低黃斑視網膜厚度，從而提高術後視力。
목적：탐토파리체강주사뢰주단항치료맥락막신생혈관적림상효과。방법수궤선취해원우2012년2월—2015년1월수치적맥락막신생혈관환자80례，근거수궤추첨원칙분위치료조여대조조각40례，소유환자도급여파리체강주사약물치료，치료조여대조조분별우각막연후4 mm좌우수직진침，완만추주뢰주단항0.05 mL(1 mg/0.1 mL)화패벌단항0.05 mL(1mg/0.1 mL)。결과술후1개월진행조사，치료조적시력유효솔위97.5%，대조조위87.5%，치료조적시력유효솔명현고우대조조(P<0.05)。술후1개월량조적황반시망막후도여술전대비차이유통계학의의(P<0.05)，동시치료조술후1개월적황반시망막후도명현소우대조조(P<0.05)。결론파리체강주사뢰주단항치료맥락막신생혈관능유효강저황반시망막후도，종이제고술후시력。
Objectiveb To investigate the clinical results of treatment of choroidal neovascularization with vitreous injection of monoclonal antibody. Methods 80 patients from 2012 February to 2015 January with choroidal neovascularization in accordance with the principle of random draw into the treatment group and the control group ,and each group has 40 patients, all patients were given intravitreal injection of medication, the treatment group and the control group in the limbus, about 4mm vertical needle slow-ly bolus injection of Ranibizumab 0.05 mL (1mg/0.1 mL) and bevacizumab 0.05 mL (1mg/0.1 mL). Results After a month investi-gation, vision therapy group effective rate was 97.5%in the control group, 87.5%had vision therapy group was significantly higher (P<0.05). Thickness and preoperative contrast macular one month after the two groups were significantly different (P<0.05), while the treatment group after one month of macular retinal thickness was significantly less than the control group (P<0.05). Conclu-sion Intravitreal injection of ranibizumab treatment of choroidal neovascularization can reduce macular thickness, thereby improv-ing visual acuity.
